Company profile: Singulex
1.1 - Company Overview
Company description
- Provider of direct molecular detection and cardiovascular monitoring solutions, including the Singulex Clarity System, an automated in vitro diagnostics platform using Single Molecule Counting technology for precise, ultra-low-level biomarker measurement across a 6-log reporting range, and the Singulex cTnI Assay for femtogram-per-milliliter cardiac troponin I quantitation to aid cardiovascular disease diagnosis and management.
Products and services
- Single Molecule Counting Technology: This custom-engineered technology quantifies biomarkers at ultra-low levels, delivering higher sensitivity and broader dynamic range than contemporary immunoassay systems for direct molecular detection
- Singulex Clarity System: This industrial-grade, fully automated in vitro diagnostics platform employs Single Molecule Counting to produce precise results across a 6-log reporting range for clinical biomarker measurements
- Singulex cTnI Assay: This lab-grade assay quantitatively measures cardiac troponin I at femtogram per milliliter levels, enabling diagnosis and management of cardiovascular disease through ultra-sensitive, precise biomarker detection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Singulex
Agilent
HQ: United States
Website
- Description: Provider of scientific and laboratory management solutions for analytical scientists and clinical researchers, offering instruments, software, and HPLC, GC & spectroscopy supplies for chemical analysis; life sciences tools for genomics, proteomics, and cell analysis; diagnostic solutions including pathology and molecular diagnostics; and products such as 8850 GC and NovoCyte Opteon.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Agilent company profile →
B-MoGen
HQ: United States
Website
- Description: Provider of genome engineering solutions, including the TcBuster Transposon System, a non-viral genetic modification method for delivering therapeutic payloads to diverse cell types, enabling rapid transgenic mammalian cell generation, multigene transfer, and CRISPR-mediated knockouts; and ScaleReady, a partnership that reduces complexity and cost in immune cell therapy and supports scalable immune cell expansion with platform, process, and product continuity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full B-MoGen company profile →
CellASIC
HQ: United States
Website
- Description: Provider of microfluidic platforms for live cell analysis, enabling long-term perfusion cell culture and dynamic flow control. The biotechnology company develops cutting-edge microfluidics technology to support superior live cell experiments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CellASIC company profile →
Ziylo
HQ: United Kingdom
Website
- Description: Provider of biomimetic glucose binding molecules (GBM) based on supramolecular chemistry for use in diabetes care, enabling Continuous Glucose Monitors (CGM) and Glucose Responsive Insulins (GRI), with a mission to help people with diabetes live more normal and longer lives.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ziylo company profile →
Bico
HQ: Sweden
Website
- Description: Provider of life science solutions to enable human organ and tissue production.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bico company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Singulex
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Singulex
2.2 - Growth funds investing in similar companies to Singulex
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Singulex
4.2 - Public trading comparable groups for Singulex
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →